Expanding the phenotypic spectrum of hereditary hemorrhagic telangiectasia (HHT): A pediatric case of ACVRL1-assocaited HHT with gastrointestinal polyposis
ACMG 2026
Jennifer Basart, Ana Maria Rodriguez Barreto
Introduction
Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant vascular disorder characterized by mucocutaneous telangiectasias and arteriovenous malformations (AVMs). HHT is most often associated with three genes involved in the transforming growth factor beta (TGF-β) signaling pathway. Variants in the ENG gene (encoding endoglin) and the ACVRL1 gene (encoding activin receptor-like kinase 1) disrupt TGF-β signaling and lead to vascular dysplasia, while variants in the SMAD4 gene (encoding TGF-4) disrupt intracellular signaling in the TGF-β/BMP pathway. Variants in the SMAD4 gene is associated with an overlapping syndrome of Juvenile Polyposis-HHT (JPHT), linking vascular malformations and gastrointestinal polyposis. However, these associations have not been reported in patients with variants in the ENG and ACVRL1 genes. Here we report a case of a young female with juvenile polyps who was found to have a likely pathogenic variant of ACVRL1.
Case Presentation
A 4-years old female participant with family history of HHT presented for genetic evaluation following biopsy-confirmed colonic polyps detected during colonoscopy. Patient was born full-term at 39 weeks, conceived naturally to a 23 years old mother, with no reported prenatal or perinatal complications, no NICU stay. Participant presented with daily rectal bleeding for 4 months and was found to have 3 juvenile polyps located in the ileocecal valve region and colon during colonoscopy. Family history significant for maternal grandfather with genetically confirmed HHT due to a pathogenetic ACVRL1 variant and colonic polyps. Physical exam revealed no cutaneous malformations or additional systemic findings.
Diagnostic Workup
An Ambry Genetics ColoNext+RNAinsight Panel was negative (20 genes associated with hereditary colon cancer). Targeted testing for the known ACVRL1 familial variant confirmed she had the same variant initially found in her grandfather (ACVRL1 c.1135G>A, [p.Glu379Lys][E379K], likely pathogenic as per GeneDx).
Treatment and Management
The patient will be managed conservatively and screened annually for signs suggestive of new polyps emerging. Genetic counseling was provided to discuss inheritance patterns, recurrence risk, and surveillance recommendations and testing of first degree relatives recommended.
Discussion
HHT is an autosomal dominant vascular disorder characterized by the development of mucocutaneous telangiectasias and visceral AVMs. Clinically, patients with HHT often present with recurrent epistaxis, mucocutaneous telangiectasias, and visceral AVMs. Diagnosis is based on Curaçao criteria, which includes spontaneous and recurrent epistaxis, multiple telangiectasias, visceral AVMs, and a family history of HHT, and is confirmed through molecular testing of genes in the TGF-β signaling pathway.
Juvenile polyposis syndrome is another autosomal dominant condition defined by multiple hamartomatous polyps throughout the GI tract. The most common variants associated with this syndrome occur in SMAD4 and BMPR1A, both within the TGF-β /BMP signaling pathway. SMAD4 variants are associated with Juvenile Polyposis-HTT (JPHT), characterized by both vascular malformations and gastrointestinal polyposis due to shared pathway dysregulation.
While GI polyposis is classically associated with SMAD4-related JPHT, the presence of juvenile polyps in this ACVRL1-associated HHT patient suggests a possibility of alternative overlap pathways that disrupt the TGF-β signaling beyond SMAD4. Recognizing this potential overlap may refine understanding of both disorders and guide future surveillance recommendations for patients with HHT.
Conclusion
This case of a pediatric patient with HHT with gastrointestinal polyposis highlights the need for further investigations into the genetic and clinical diversity of HHT. The observed co-occurrence of vascular malformations and gastrointestinal polyposis in this ACVRL1-associated case suggests a potential mechanistic link between TGF-β signaling dysregulation and mucosal proliferation. Continued studies are essential to clarify this association and to guide future surveillance recommendations for patients and families affected by HHT, regardless of genotype.
Related publications